Fly News Breaks for February 27, 2020
Feb 27, 2020 | 07:08 EDT
Barclays analyst Carter Gould started coverage of Amgen (AMGN) with an Equal Weight rating and $235 price target. He believes the acquisition of Otezla from Celgene (CELG) should provide a boost to 2020 revenues, but only modestly improves the company's profile after 2020, which he sees being below biopharma peers. The analyst initiated coverage of the U.S. Biopharmaceuticals industry with a Positive view citing waning near-term concerns on drug pricing reform, evidence of innovation and attractive valuations.
News For AMGN From the Last 2 Days